Jiangsu Wuzhong Pharmaceutical Group Corporation announced a equity round of funding for gross proceeds of CNY 340 million with existing investor JiangSu WuZhong Pharmaceutical Development Co., Ltd. on January 5, 2022. As a part of the round, the registered capital of the company will increase from CNY 400 million to CNY 740 million. Post the capital increase, the investor will retain its 100% stake in the company.